XNYS · Medical Care Facilities
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$179.28-3.37%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Valuation
What to watch
- Quality & growth
- Sentiment Signal
Quality & growth
30%43Weak
- Revenue growth 6.3%
- EPS growth 20.2%
Valuation
25%61Positive
- P/E 14.0
- EV/Sales 1.6
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Revenue growth (industry)Top 91%
Gross margin (industry)Top 50%
P/E (industry)Cheaper than 82%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
50/100Moderate
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Strong Sell
0 buy · 4 sell · 4 neutral of 8 votes
TickerWhale reads DVA's technical setup as middling at 50/100, not yet ranked against the universe in this run. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
1 / 9constructive
- vs 200-day-0.3%
- vs 50-day-1.9%
Momentum
Mixed
- RSI (14)45 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength8· weak trend
- MACD (12,26,9)sell(histogram -0.210)
How the classic verdict is reached
Moving averages (9) agree on sell — 1 buy vs 7 sell — and carry one vote between them.
Oscillators (7) vote individually: 0 buy · 3 sell · 4 neutral.
Result — 0 buy vs 4 sell of 8 votes = Strong Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)14.0
- P/S (TTM)0.9
- P/B—
- EV/EBITDA—
- EV/Sales1.6
- PEG0.69
Profitability & returns
- Gross margin30.7%
- Net margin6.2%
- ROE—
- Debt/Equity—
Growth
- Revenue growth (YoY)6.3%
- EPS growth (YoY)20.2%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $11.8B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DVACurrentDaVita | — | 50 | 14.0 | — | — | 1.6 | $179.28 | -3.37% | +6.3% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.